Lorena Lupinacci Selected Research

Nivolumab

1/2023	Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.
1/2022	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
1/2020	Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
11/2019	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lorena Lupinacci Research Topics

Disease

8	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2023 - 01/2018
3	Neoplasms (Cancer) 01/2023 - 11/2019
1	Exanthema (Rash) 01/2022

Drug/Important Bio-Agent (IBA)

4	NivolumabIBA 01/2023 - 11/2019
3	B7-H1 AntigenIBA 01/2023 - 11/2019
3	IpilimumabIBA 01/2023 - 11/2019
2	durvalumabIBA 11/2023 - 01/2022
2	Immune Checkpoint InhibitorsIBA 11/2023 - 06/2021
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	CrizotinibIBA 01/2018

Therapy/Procedure

3	Drug Therapy (Chemotherapy) 01/2023 - 01/2020
2	Immunotherapy 01/2023 - 01/2020
1	Radiotherapy 01/2022
1	Therapeutics 01/2022